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ence the risk of common, sporadic forms of autism remains open. It
is now widely accepted that rare genetic variants could play an im-
portant role in susceptibility to common diseases. In light of Cartier
et al.'s results, major resequencing efforts of the SLC6A3 and STX1A
genes should be undertaken in large cohorts of individuals with
autism, with signiﬁcant insights into disease biology likely from
these results.Dysfunction in dopaminergic signaling may be an underlying cause
of different neuropsychiatric disorders, including schizophrenia,
bipolar disorder, attention-deﬁcit hyperactivity disorder (ADHD),
and autism (Money & Stanwood, 2013). The dopamine (DA) trans-
porter (DAT) plays a critical role in regulating the strength of dopa-
minergic tone by clearing extracellular DA (Vaughan & Foster, 2013).
Interestingly, DAT is the site of action for psychostimulants such as am-
phetamine (AMPH), which is thought to elevate extracellular DA levels
by competitively inhibiting DA uptake, ultimately causing reverse
transport of DA (DA efﬂux) (Robertson et al., 2009). Growing evidence
indicates a genetic link between DAT and autism (Bowton et al., 2014;
Hamilton et al., 2013). The work by Cartier et al. (in press) in this
issue of EBioMedicine has studied the functional consequences of a
nonsynonymous genetic variant in the human DAT gene (SLC6A3)
which converts Arg51 to tryptophan (SLC6A3 R51W) in a family with
autism. Moreover, the authors showed that another autism-causing
rare variant in the syntaxin 1A gene (STX1A), which converts Arg26
to glutamine (STX1A R26Q), disrupts the molecular mechanisms of re-
verse transport of DA. Based on these results, they concluded that rare
variants causing a signiﬁcant inhibition of reverse transport of DA may
play a pathogenic role in autism. While it has been known for many
years that reverse transport of DA may be involved in the maintenance
of an optimal range of DA levels (Leviel, 2001), its exact role in the path-
ogenesis of neuropsychiatric disorders remains to be determined. The
molecular analyses provided in the paper by Cartier et al. (in press)
elegantly demonstrate that alterations in reverse transport of DA may
be involved in the pathogenesis of autism symptoms at least in the
speciﬁc pedigrees. However, the question as to whether such rareom.2015.01.007.
. This is an open access article underAnother interesting implication of the work by Cartier and col-
leagues lies in unraveling the therapeutic potential of DA reverse trans-
port in autism. Starting from the observation that rare autism-causing
variants are associated with inhibition of reverse transport of DA, it
could be hypothesized that psychostimulants may serve as a potential
therapeutic aid in autism. Notably, not only have psychostimulants
been suggested to be effective for ADHD-like symptoms in autism spec-
trumdisorder individuals, but theprevalence rates of their use in autism
are also strikingly increasing (Dalsgaard et al., 2013). It should be noted,
however, that AMPH (which is known to cause reverse transport of DA)
has been also shown to elicit autism-like symptoms including stereo-
typed behaviors and social impairments in animal models (Moy et al.,
2013, 2014). Based on this evidence, the conclusion that increasing
the reverse transport of DA could represent a novel therapeutic target
in autism per se (and not for the ADHD-like symptoms in autism) is
probably too premature. However, it is becoming increasingly clear
that the reverse transport of DA could be one of the key mechanisms
involved in the ﬁne-tuning of DA levels in the synapse. In this scenario,
the work by Cartier and colleagues is relevant in unraveling how
disruption of such synaptic dopaminergic ﬁne-tuning could ultimately
result in autism.Author Contribution
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